Biopharmaceutical company AstraZeneca plc (LSE/STO/NYSE: AZN) and its Japanese pharmaceutical partner Daiichi Sankyo (TYO: 4568) said on Tuesday that the European Commission has approved Enhertu (trastuzumab deruxtecan) as a monotherapy for the adjuvant treatment of adults with resected HER2-positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2-targeted treatment.
The approval, based on results from the Phase III DESTINY-Breast05 trial, marks the first EU approval of Enhertu in an early breast cancer setting with curative intent.
In the trial, Enhertu was found to reduce the risk of invasive disease recurrence or death by 53% compared with trastuzumab emtansine (T-DM1), with a hazard ratio of 0.47 (95% confidence interval 0.34-0.66; p
Abbott reports 30-day results from clinical trial of SonicForce Coronary IVL System
Bambusa Therapeutics prices upsized initial public offering
Phrontline Biopharma reports preliminary safety and antitumour activity for TJ101
Daiichi Sankyo secures EMA validation for two triple-combination cholesterol therapies
TME Pharma signs exclusive negotiation agreement with Japan's TMS for NOX-A12 rights
Ascletis reports positive US Phase II topline results for ASC30 in diabetes
Evogene targets acute graft-versus-host disease for AI-driven drug discovery programme
Genmab reports 50% reduction in risk of death in Phase 3 head and neck cancer trial
Novocure and Verastem to evaluate combination therapy for pancreatic cancer
Astellas and Audax Biosciences sign exclusive option and licence agreement for DAX-044
Thor Medical signs three-year isotope supply agreement with Medicines Discovery Catapult
Enhertu wins EU approval for HER2-positive early breast cancer treatment
Riboscience reports Phase 1a/b overall survival data for ENPP1 inhibitor RBS2418